Biomorphik App with MyFiziq technology released on Google and Apple
Just a fortnight after MyFiziq Limited (ASX:MYQ) announced that the Biomorphik App integrated with MyFiziq’s technology had been registered with Google Play and Apple Store for release approval, management has today confirmed that the app has been released on both platforms.
In line with the initial product release, Biomorphik will commence a comprehensive B2C marketing strategy to draw users to the new platform with the first stage allowing people to monitor their bodies closely and pre-empt potential issues before they become prohibitive to the user’s health.
At its core, Biomorphik is a behavioural change company with a key goal being to improve the health and wellness of people at a whole-of-society level through better creation, measurement, storage, analysis, and access to data.
The technology is highly complementary with MyFiziq’s patented proprietary image capture and dimensioning technology that enables its users to check, track, and accurately assess their dimensions and vital signs using only a smartphone privately on-device.
Pricing provides highly competitive option for consumers
Under the terms of the commercial contracts, Biomorphik has given an undertaking to deliver 100,000 active monthly users to MyFiziq.
In the event this target is not achieved, MyFiziq has a right to terminate the agreements between the parties.
Biomorphik will offer both a monthly subscription at AUD$22.99 per month for unlimited scans, as well as a yearly subscription payment option with a significant discount at AUD$142.99 per year for unlimited scans to consumers.
This pricing represents a highly attractive offering relative to other players in the sector.
On the score of affordability, MyFiziq chief executive Vlado Bosanac said, ‘’When you consider a single Dexa body composition scan can cost up to AUD$80.00, the monthly fee of AUD$22.99 is an extremely cost-effective option.
‘’The user can scan as many times as they wish to track body composition changes, empowering the user to make better decisions regarding their health and wellness.’’
Bosanac went on to say, ‘’With the applications now live and available for download, Nathaniel (CEO of Biomorphik) is programming a well-formulated marketing approach to the release over the first quarter of 2021.
‘’Once this commences, we will assist Nathaniel and Biomorphik with their campaign as needed, and I believe this will be the first of the releases to take a more aggressive approach to customer on-boarding as it forms such an integral part of their customer journey and retention, through real data and supervision.
‘’I encourage our shareholders and stock followers to try the Biomorphik app now that it has been released on the Australian iOS and Google Play app stores.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.